{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:59:26Z","timestamp":1789185566159,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ajem.2024.10.040","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:31:41Z","timestamp":1730107901000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department"],"prefix":"10.1016","volume":"87","author":[{"given":"Cierra N.","family":"Treu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Stilwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunah","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Acquisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.ajem.2024.10.040_bb0005","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2024.10.040_bb0010","article-title":"Global burden of bacterial skin diseases: a systematic analysis combined with sociodemographic index, 1990-2019","volume":"9","author":"Xue","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ajem.2024.10.040_bb0015","author":"Cairns"},{"issue":"5","key":"10.1016\/j.ajem.2024.10.040_bb0020","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jaad.2020.11.021","article-title":"Burden, risk factors, and infectious complications of cellulitis and erysipelas in US adults and children in the emergency department setting","volume":"84","author":"Ren","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ajem.2024.10.040_bb0025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2334-14-296","article-title":"Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009","volume":"14","author":"Suaya","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.ajem.2024.10.040_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.ajem.2024.10.040_bb0035","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/ph16091304","article-title":"New antimicrobials for gram-positive sustained infections: a comprehensive guide for clinicians","volume":"16","author":"Carcione","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10.1016\/j.ajem.2024.10.040_bb0040","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/antibiotics11080996","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ajem.2024.10.040_bb0045","series-title":"Dalvance Package Insert","year":"2018"},{"issue":"5","key":"10.1016\/j.ajem.2024.10.040_bb0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ajem.2024.10.040_bb0055","series-title":"Orbactiv and Kimyrsa Package Inserts","year":"2022"},{"issue":"4","key":"10.1016\/j.ajem.2024.10.040_bb0060","first-page":"959","article-title":"Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments","volume":"13","author":"Lupia","year":"2023","journal-title":"Life (Basel)"},{"issue":"10","key":"10.1016\/j.ajem.2024.10.040_bb0065","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against gram-positive cocci from clinical infections in the USA and Europe 2015-16","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ajem.2024.10.040_bb0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A two-dose oritavancin regimen using pharmacokinetic estimation analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jemermed.2021.09.015","article-title":"Diagnosis and management of cellulitis and abscess in the emergency department setting: an evidence-based review","volume":"62","author":"Long","year":"2022","journal-title":"J Emerg Med"},{"issue":"8","key":"10.1016\/j.ajem.2024.10.040_bb0080","doi-asserted-by":"crossref","first-page":"474","DOI":"10.15171\/ijhpm.2019.26","article-title":"Leaving against medical advice from in-patients departments rate, reasons and predicting risk factors for re-visiting hospital retrospective cohort from a tertiary care hospital","volume":"8","author":"Hasan","year":"2019","journal-title":"Int J Health Policy Manag"},{"issue":"15","key":"10.1016\/j.ajem.2024.10.040_bb0085","doi-asserted-by":"crossref","first-page":"7768","DOI":"10.3390\/ijerph18157768","article-title":"Assessing medication adherence barriers to short-term oral antibiotic treatment in primary care-development and validation of a self-report questionnaire (BIOTICA)","volume":"18","author":"Haag","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.ajem.2024.10.040_bb0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1155\/2013\/754897","article-title":"Outpatient parenteral antimicrobial therapy for surgery patients: a comparison with previous standard of care","volume":"24","author":"Yang","year":"2013","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"7","key":"10.1016\/j.ajem.2024.10.040_bb0095","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ajem.2016.04.022","article-title":"Intravenous home infusion therapy instituted from a 24-hour clinical decision unit for patients with cellulitis","volume":"34","author":"Rentala","year":"2016","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2024.10.040_bb0100","article-title":"Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohort","volume":"10","author":"Billmeyer","year":"2023","journal-title":"Ther Adv Infect Dis"},{"issue":"2","key":"10.1016\/j.ajem.2024.10.040_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ajem.2019.158442","article-title":"Finding the niche: an interprofessional approach to defining oritavancin use criteria in the emergency department","volume":"38","author":"Baxa","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ajem.2024.10.040_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s40801-020-00201-y","article-title":"Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis","volume":"7","author":"Helton","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"Suppl. 1","key":"10.1016\/j.ajem.2024.10.040_bb0115","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1093\/ofid\/ofy210.1534","article-title":"Expanding Kentucky\u2019s \u201cone and done\u201d tradition: lipoglycopeptide administration in the emergency department at a tertiary, academic medical center","volume":"5","author":"Burgess","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.ajem.2024.10.040_bb0120","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ajem.2017.11.037","article-title":"Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit","volume":"36","author":"Koziatek","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2024.10.040_bb0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ajem.2022.07.013","article-title":"Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department","volume":"60","author":"Sacdal","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"10","key":"10.1016\/j.ajem.2024.10.040_bb0130","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/acem.14258","article-title":"Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections","volume":"28","author":"Talan","year":"2021","journal-title":"Acad Emerg Med"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s12913-018-3751-0","article-title":"Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department","volume":"18","author":"Almarzoky Abuhussain","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ajem.2024.10.040_bb0145","doi-asserted-by":"crossref","unstructured":"Lodise TP, Fan W, Sulham KA. Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis. Hosp Pract (1995) 2015;43(3):137\u201343https:\/\/doi.org\/10.1080\/21548331.2015.1076325.","DOI":"10.1080\/21548331.2015.1076325"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5811\/westjem.2014.11.24133","article-title":"Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection","volume":"16","author":"Talan","year":"2015","journal-title":"West J Emerg Med"},{"issue":"7","key":"10.1016\/j.ajem.2024.10.040_bb0155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/14787210.2023.2214727","article-title":"Direct or early discharge of acute bacterial skin and skin structure infection patients from the emergency department\/unit: place in therapy of dalbavancin","volume":"21","author":"Oliva","year":"2023","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40360-020-00452-z","article-title":"Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs","volume":"21","author":"Ahiskali","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02385-22","article-title":"Evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital","volume":"11","author":"Lueking","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"7","key":"10.1016\/j.ajem.2024.10.040_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ajem.2024.10.040_bb0175","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1093\/ofid\/ofaa439.432","article-title":"Dalbavancin use in patients with substance use disorders","volume":"7","author":"Streifel","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ajem.2024.10.040_bb0180","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212559","article-title":"Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs","volume":"7","author":"Gonzalez","year":"2018","journal-title":"Drugs Context"},{"issue":"3","key":"10.1016\/j.ajem.2024.10.040_bb0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.clinthera.2016.01.007","article-title":"Identification of patient characteristics influencing setting of care decisions for patients with acute bacterial skin and skin structure infections: results of a discrete choice experiment","volume":"38","author":"Lane","year":"2016","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ajem.2024.10.040_bb0190","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.annemergmed.2018.09.020","article-title":"Identification of clinical characteristics associated with high-level care among patients with skin and soft tissue infections","volume":"73","author":"Mower","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.ajem.2024.10.040_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/1120009X.2022.2134616","article-title":"Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol","volume":"35","author":"Durante-Mangoni","year":"2023","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.ajem.2024.10.040_bb0200","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","article-title":"Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital","volume":"48","author":"Pollack","year":"2015","journal-title":"J Emerg Med"},{"issue":"3","key":"10.1016\/j.ajem.2024.10.040_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248129","article-title":"Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital","volume":"16","author":"Saddler","year":"2021","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ajem.2024.10.040_bb0210","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s11606-018-4430-x","article-title":"National estimates of emergency department visits for antibiotic adverse events among adults-United States, 2011-2015","volume":"33","author":"Geller","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.ajem.2024.10.040_bb0215","article-title":"A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open forum","volume":"5","author":"Redell","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"11","key":"10.1016\/j.ajem.2024.10.040_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of gram-positive infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.ajem.2024.10.040_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ajem.2024.10.040_bb0230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/TCRM.S271445","article-title":"Review: a safety profile of dalbavancin for on- and off-label utilization","volume":"17","author":"Simonetti","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ajem.2024.10.040_bb0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ajem.2022.02.006","article-title":"Real world utilization of dalbavancin at a rural community emergency department","volume":"54","author":"Dolan","year":"2022","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2024.10.040_bb0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajem.2021.01.050","article-title":"Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: a case series","volume":"43","author":"Dretske","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ajem.2024.10.040_bb0245","doi-asserted-by":"crossref","first-page":"S705","DOI":"10.1093\/ofid\/ofy210.2023","article-title":"Dalbavancin use in emergency department and observation unit to prevent inpatient admission for acute bacterial skin and skin structure infection (ABSSSI)","volume":"5","author":"Ford","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.ajem.2024.10.040_bb0250","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.japh.2020.11.001","article-title":"Impact of clinical decision support on oritavancin prescribing in the emergency department","volume":"61","author":"Treu","year":"2021","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.ajem.2024.10.040_bb0255","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajem.2020.01.061","article-title":"Use of a telehealth follow-up system to facilitate treatment and discharge of emergency department patients with severe cellulitis","volume":"41","author":"Koziatek","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"11","key":"10.1016\/j.ajem.2024.10.040_bb0260","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/1060028019855159","article-title":"Dalbavancin use in the emergency department setting","volume":"53","author":"Patel","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.ajem.2024.10.040_bb0265","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/21548331.2018.1506673","article-title":"Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States","volume":"46","author":"Keyloun","year":"2018","journal-title":"Hosp Pract"},{"key":"10.1016\/j.ajem.2024.10.040_bb0270","author":"The Joint Commission"},{"issue":"RR6","key":"10.1016\/j.ajem.2024.10.040_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6506a1","article-title":"Core elements of outpatient antibiotic stewardship","volume":"65","author":"Sanchez","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0280","article-title":"Accuracy of CREST guideline in management of cellulitis in emergency department; a systematic review and meta-analysis","volume":"9","author":"Akhavan","year":"2021","journal-title":"Arch Acad Emerg Med"},{"issue":"4","key":"10.1016\/j.ajem.2024.10.040_bb0285","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40121-018-0212-3","article-title":"Development of a risk-scoring tool to determine appropriate level of care in acute bacterial skin and skin structure infections in an acute healthcare setting","volume":"7","author":"Claeys","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"12","key":"10.1016\/j.ajem.2024.10.040_bb0290","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz475","article-title":"Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with oritavancin or vancomycin for a skin infection in the outpatient setting","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0295","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","article-title":"Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations","volume":"38","author":"Lodise","year":"2016","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ajem.2024.10.040_bb0300","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/21548331.2016.1230466","article-title":"Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion","volume":"44","author":"Bosso","year":"2016","journal-title":"Hosp Pract"},{"issue":"7","key":"10.1016\/j.ajem.2024.10.040_bb0305","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/13696998.2019.1591423","article-title":"Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department","volume":"22","author":"Keyloun","year":"2019","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.ajem.2024.10.040_bb0310","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40261-015-0365-8","article-title":"Use of oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics: a US hospital budget impact analysis","volume":"36","author":"Jensen","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"Suppl. 1","key":"10.1016\/j.ajem.2024.10.040_bb0315","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12941-022-00529-z","article-title":"Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: a systematic review and meta-analysis","volume":"21","author":"Liu","year":"2022","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"10.1016\/j.ajem.2024.10.040_bb0325","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/antibiotics12050900","article-title":"In vitro activities of ceftobiprole, dalbavancin, tedizolid and comparators against clinical isolates of methicillin-resistant Staphylococcus aureus associated with skin and soft tissue infections","volume":"12","author":"Maraki","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"10.1016\/j.ajem.2024.10.040_bb0330","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/1120009X.2023.2259673","article-title":"Oritavancin in vitro activity against gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY antimicrobial surveillance program (2010-2019)","volume":"35","author":"Pfaller","year":"2023","journal-title":"J Chemother"},{"issue":"3","key":"10.1016\/j.ajem.2024.10.040_bb0335","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkac434","article-title":"Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections","volume":"78","author":"Al Janabi","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ajem.2024.10.040_bb0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"10.1016\/j.ajem.2024.10.040_bb0345","doi-asserted-by":"crossref","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","article-title":"Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ajem.2024.10.040_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ajem.2024.10.040_bb0355","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01667-21","article-title":"Activity of oritavancin against gram-positive pathogens causing bloodstream infections in the United States over 10 years: focus on drug-resistant enterococcal subsets (2010-2019)","volume":"66","author":"Carvalhaes","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajem.2024.10.040_bb0360","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2024.10.040_bb0365","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajem.2024.10.040_bb0370","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2024.10.040_bb0375","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073567572400559X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073567572400559X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T20:29:47Z","timestamp":1734035387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073567572400559X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":75,"alternative-id":["S073567572400559X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2024.10.040","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2024.10.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}